Induction of tolerance to factor VIII by transient co‐administration with rapamycin
暂无分享,去创建一个
B. Sack | R. Herzog | C. Mah | D. Markusic | B. Moghimi | B. Moghimi | S. Nayak | C. Mah | S. Nayak | B. Sack | Sushrusha Nayak
[1] D. Scott,et al. B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] K. Peerlinck,et al. Mild haemophilia: a disease with many faces and many unexpected pitfalls , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[3] S. Kaveri,et al. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. , 2010, Blood.
[4] H. Daniell,et al. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice , 2010, Proceedings of the National Academy of Sciences.
[5] M. Franchini,et al. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] H. Ochs,et al. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. , 2009, Blood.
[7] S. Ziegler,et al. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. , 2009, Blood.
[8] H. Ertl,et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] M. Atkinson,et al. Prophylactic immune tolerance induced by changing the ratio of antigen‐specific effector to regulatory T cells , 2009, Journal of thrombosis and haemostasis : JTH.
[10] E. James,et al. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. , 2009, Blood.
[11] B. Brown,et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells. , 2009, Blood.
[12] R. Herzog,et al. Role of regulatory T cells in tolerance to coagulation factors , 2009, Journal of thrombosis and haemostasis : JTH.
[13] D. Wechsler,et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome , 2009, British journal of haematology.
[14] K. Ghosh,et al. Immune Response to FVIII in Hemophilia A: An Overview of Risk Factors , 2009, Clinical reviews in allergy & immunology.
[15] G. Freeman,et al. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. , 2008, Blood.
[16] E. James,et al. T‐cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self‐peptide , 2007, Journal of thrombosis and haemostasis : JTH.
[17] K. Ponder,et al. High expression reduces an antibody response after neonatal gene therapy with B domain‐deleted human factor VIII in mice , 2007, Journal of thrombosis and haemostasis : JTH.
[18] R. Herzog,et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. , 2007, Blood.
[19] M. Battaglia,et al. Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1 , 2006, The Journal of Immunology.
[20] D. DiMichele. Immune tolerance: critical issues of factor dose, purity and treatment complications , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.
[21] K. Sullivan,et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). , 2006, Blood.
[22] H. Ochs,et al. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. , 2005, Blood.
[23] D. Scott,et al. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. , 2005, Blood.
[24] Jun Liu,et al. Rapamycin Induces Heme Oxygenase-1 in Human Pulmonary Vascular Cells: Implications in the Antiproliferative Response to Rapamycin , 2003, Circulation.
[25] A. Sharpe,et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia AJ. Qian, M. Collins, A.H. Sharpe, et al. Blood 95:1324–1329, 2000 , 2000 .
[26] H. Kazazian,et al. Inhibitor Antibody Development and T Cell Response to Human Factor VIII in Murine Hemophilia A , 1999, Thrombosis and Haemostasis.
[27] S. Antonarakis,et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A , 1995, Nature Genetics.
[28] P. Thompson,et al. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. , 2009, Blood.
[29] R. Negrin,et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. , 2008, Blood.